Go Pro
LON:NIOX

NIOX Group Interim Earnings Report

NIOX Group logo
GBX 57.36 -0.44 (-0.76%)
As of 07/13/2026 12:03 PM Eastern

NIOX Group EPS Results

Actual EPS
GBX 1.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NIOX Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NIOX Group Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NIOX Group Earnings Headlines

NIOX Group PLC NIOX
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
Top UK Penny Stocks To Watch In March 2026
See More NIOX Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NIOX Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NIOX Group and other key companies, straight to your email.

About NIOX Group

NIOX Group (LON:NIOX) is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence.

View NIOX Group Profile